Colorectal Cancer Market to Reach US$ 24.08 Billion by 2028

The Colorectal Cancer Market is witnessing steady growth as the global burden of colorectal cancer continues to rise and healthcare systems increasingly prioritize early diagnosis and advanced treatment solutions. According to recent market insights, the colorectal cancer market is expected to grow from US$ 18,619.3 million in 2022 to US$ 24,078.5 million by 2028, registering a compound annual growth rate (CAGR) of 3.3% during 2022-2028. This growth reflects continuous advancements in diagnostic technologies, targeted therapies, and screening programs aimed at improving survival outcomes.

Check valuable insights in the Colorectal Cancer Market report. You can easily get a sample PDF of the report - https://www.theinsightpartners.com/sample/TIPRE00006881?utm_source=OpenPr&utm_medium=10457

Colorectal cancer remains one of the most commonly diagnosed cancers worldwide, particularly among aging populations. Rising awareness, improved access to diagnostic tools, and increasing adoption of personalized medicine are significantly influencing the expansion of the Colorectal Cancer Market.

Market Overview-

The Colorectal Cancer Market is driven by increasing incidence rates, technological advancements in molecular diagnostics, and the development of innovative therapeutic modalities. Governments and healthcare organizations across the globe are investing in national screening programs to promote early detection, which is critical for improving patient prognosis and reducing treatment costs.

Advancements in biomarker-based testing, imaging technologies, and minimally invasive procedures have transformed colorectal cancer diagnosis and management. In parallel, pharmaceutical companies are expanding their oncology portfolios through targeted therapies, immunotherapies, and combination treatments, supporting sustained market growth.

Segmentation Analysis-

By Modality

Diagnosis Type
Therapy Type
Imaging Type
By End User

Hospitals and Diagnostic & Research Laboratories

Access full description of the report @ https://www.theinsightpartners.com/reports/colorectal-cancer-market

Market Insights-

Rise in Incidence of Colorectal Cancer-

Colorectal cancer is one of the most commonly found and lethal cancers developed in individuals with the combined influence of genetic and environmental factors. According to the World Health Organization (WHO), colorectal cancer is the third most prevalent form of cancer, with ~1.93 million global cases in 2020, and an increase of ~70% in colorectal cancer cases worldwide is expected by 2030. Furthermore, according to the National Institute of Health, colorectal cancer (CRC) accounts for over 9% of all cancer incidences and is a major cause of morbidity and mortality worldwide in 2020. Furthermore, colorectal cancer mortality and incidence rates vary globally, and ~916,000 deaths in 2020 were due to colorectal cancer. It is the third most common cancer in men and the second most common cancer in women. The lifetime risk of developing colorectal cancer is about 1 in 23 for men and 1 in 25 for women. Therefore, colorectal cancer was identified as the third most common cancer and the second most death-causing cancer.

Market Leaders and Key Company Profiles-

Amgen Inc.
Bruker Corporation
Epigenomics AG
Clinical Genomics Technologies Pty Ltd.
VolitionRx Limited
Novigenix SA
Hoffmann-La Roche AG
Abbott
EDP Biotech

Factors such as the increasing prevalence of colorectal cancer, product launches, and benefits offered by generic drugs are driving the global colorectal cancer market growth. However, pricing pressure on drug manufacturers is hindering the market growth.

Colorectal cancer is a malignant tumor of the large intestine's inner wall. This is due to abnormal cell growth that can invade or spread to other body parts. Colorectal cancer is commonly caused by inflammatory bowel disease and genetic inheritance. Fatigue, diarrhea or constipation, shortness of breath, weakness, change in bowel habits, red or dark blood in stool, weight loss, abdominal pain, and bloating are a few common symptoms. Colorectal cancer is classified into four stages: stage 0, stage I-cancer in the inner layers of the colon, stage II-cancer spreads through the muscle wall of the colon, stage III-cancer spreads to lymph nodes, and stage IV-cancer spreads to other organs. Colorectal cancer can be treated with chemotherapy, radiotherapy, and surgery.

Get Premium Research Report of Colorectal Cancer Market Size and Growth Report at: https://www.theinsightpartners.com/buy/TIPRE00006881?utm_source=OpenPr&utm_medium=10457

Conclusion-

The Colorectal Cancer Market is positioned for steady growth through 2028, supported by rising disease prevalence, technological advancements in diagnostics and imaging, and the continuous development of innovative therapeutic options. With market value projected to reach US$ 24,078.5 million by 2028, stakeholders across healthcare, pharmaceuticals, and diagnostics are expected to benefit from ongoing investments in early detection and personalized treatment approaches. As awareness increases and screening programs expand globally, the Colorectal Cancer Market will continue to play a critical role in improving patient outcomes and shaping the future of oncology care.

Related Reports:

Cancer Therapy Market - https://www.theinsightpartners.com/reports/cancer-therapy-market

Cancer Vaccines Market - https://www.theinsightpartners.com/reports/cancer-vaccines-market

Cervical Cancer Test Market - https://www.theinsightpartners.com/reports/cervical-cancer-test-market

Lung Cancer Surgery Market - https://www.theinsightpartners.com/reports/lung-cancer-surgery-market

Contact Us:
• If you have any queries about this report or if you would like further information, please get in touch with us:
• Contact Person: Ankit Mathur
• E-mail: ankit.mathur@theinsightpartners.com
• Phone: +1-646-491-9876

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

This release was published on openPR.